NextCell Pharma

NextCell Pharma Tangible Book Value per Share

The Tangible Book Value per Share of NextCell Pharma (NXTCL.ST) as of Oct 22, 2026 is 0.60 SEK. In the previous year, Tangible Book Value per Share was 0.61 SEK — a change of -1.79% (lower).

Tangible Book Value per Share

0.60SEK

YoY

-1.79%

Last updated:

Tangible Book Value per Share of NextCell Pharma is 2025 0.60 SEK. Tangible Book Value per Share of NextCell Pharma was 2024 0.61 SEK. It decreases by -1.79% lower compared to the previous year.

The NextCell Pharma Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
0.05 SEK
Jan 1, 2019
0.21 SEK
Jan 1, 2020
0.24 SEK
Jan 1, 2021
1.35 SEK
Jan 1, 2022
1.04 SEK
Jan 1, 2023
0.68 SEK
Jan 1, 2024
0.61 SEK
Jan 1, 2025
0.60 SEK
The NextCell Pharma Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
0.60SEK-1.79%
0.61SEK-10.73%
0.68SEK-34.46%
1.04SEK-23.02%
1.35SEK+472.47%
0.24SEK+14.19%
0.21SEK+355.44%
0.05SEK-73.57%
0.17SEK+181.96%
0.06SEK-30.77%
0.09SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

NextCell Pharma Stock analysis

What does NextCell Pharma do? NextCell Pharma AB develops stem cell therapies using a proprietary selection algorithm, focusing on autoimmune diabetes and other autoimmune diseases. The company operates a tissue establishment and biobank as a healthcare provider, commercializing mesenchymal stem cell products. Its primary revenue comes from the development and sale of these stem cell therapies to healthcare institutions and research organizations. The firm's business model centers on R&D for stem cell products, with the tissue establishment and biobank supporting its research activities. NextCell targets healthcare providers and research entities as key customers for its stem cell therapies and biobank services. NextCell Pharma AB's revenue streams are derived from the commercialization of its stem cell therapies, leveraging its proprietary technology for autoimmune disease treatment. The company's focus on mesenchymal stem cell products positions it within the healthcare provider segment, specifically serving institutions requiring advanced cell-based treatments. NextCell Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextCell Pharma stock

Tangible Book Value per Share of NextCell Pharma is 0.60 SEK in 2025.

Tangible Book Value per Share of NextCell Pharma changed from 0.61 SEK to 0.60 SEK, representing a -1.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share NextCell Pharma since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — NextCell Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — NextCell Pharma